Further Strengthens Business Development Team with Key Hire

PARSIPPANY, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences subsidiary, Interpace Pharma Solutions today announced that it is continuing to expand a previously announced partnership agreement to jointly develop, promote and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (Genecast) of the Peoples Republic of China (PRC). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC. Interpace is sending members of its technical/scientific and business development teams to China this week to begin the tech transfer requirements to support over $3 million of recently secured new business with global pharmaceutical companies.

Michael McCartney, Chief Commercial Officer of Interpace Pharma Solutions commented, We will be joining the Genecast business development team in China to jointly promote our capabilities of tumor profiling testing and clinical testing services in China and will be traveling to Beijing, Suzhou and Shanghai to meet with Genecast pharma customers who are in need of Interpace Pharma Solutions services Mr. McCartney also added We are thrilled to announce the addition of Gordon Vansant, Ph.D. a highly regarded industry expert to our BD team. Dr. Vansant has deep relationships and contacts in China to further strengthen and expand our penetration in China and Asia and will lead our BD efforts in the Southwest US, headquartered out of San Diego.

Du Bo, Co-Founder and CEO of Genecast, said, We are excited that the partnership with Interpace Pharma Solutions is already working and we believe will strengthen our capabilities to provide our customers with high-quality, streamlined one-stop testing services globally. Interpace Pharma Solutions development is in line with our strategy of helping pharmaceutical and biotech companies on a global basis accelerate their biomarker-driven drug development and drive precision medicine forward.

Jack Stover, President & CEO of Interpace Biosciences commented, We are pleased with the new business already being booked as a result of our relationship with such a high-quality partner as Genecast and we are pleased to have such an experienced and successful executive as Dr. Vansant join our Pharma Solutions BD team. We look forward to expanding our partnership with Genecast as well as expanding our international capabilities in Europe, Asia and elsewhere in the near future, concluded Stover.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Pharma Solutions is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP).

For more information, please visit Interpace Biosciences website atwww.interpace.com.

Genecast (Beijing) Biotechnology Co. Ltd.

Genecast is a leader in offering diagnostic products & services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the Peoples Republic of China (PRC). Genecasts laboratories have met all applicable standards for accreditation including accreditation from the CAP and earned top marks in a number of external quality assessments carried out by CAP, EMQN, the Clinical Test Center of the National Health Commission of China and Center of Clinical Laboratories of Shanghai.

Genecast has formed collaborations with more than 20 pharmaceutical and biotech companies in providing comprehensive pre-clinical and clinical testing services.

For more information, please visit Genecasts website at http://english.genecast.com.cn.

Media Contact:Dan ChenGenecast (Beijing) Biotechnologychen.dan@genecast.com.cn

Forward Looking Statements on Behalf of Interpace Biosciences

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other SEC filings. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

INTERPACE CONTACTS:Investor RelationsJoseph Green, Edison Groupjgreen@edisongroup.com

Read the original here:
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China - GlobeNewswire

Student Connection

The Biotech Student Connection is a great way to get involved in your field of study.

Student Connection

It is our mission to serve the greater Austin area by providing exceptional quality biotechnology education.

Read more

The ACC Biotechnology Program is frequently involved in news worthy industry projects.

ACC Biotech News

The Biotechnology Program offers a variety of cutting-edge certificates and degrees tailored for people wanting to enter into the bioscience and biotechnology workplace. We offer Entry-Level Certificates, an Associate Degree and Post-Baccalaureate Certificate training.

Our degrees focus on a hands-on training approach spanning topics from basic laboratory skills such as micropipetting and solution preparation to more advanced skills such as quantitative PCR, HPLC and cell culture. In addition, the program also provides specialized training in bioinformatics, regulatory affairs, and biomanufacturing.

The AAS and ATC degrees have a capstone internship course where students apply all their new skills on the job. Most graduates are hired within their internship; others that are seeking employment find jobs in a few months after graduation.

We offer both day and night classes in both Round Rock and Austin, in addition to online and summer course offering to accommodate both day-time and night-time (working) students. If you want to learn more about this exciting hands-on program, or to get registered, please contact us at512-223-5915, email: biotech@austincc.edu or submit this brief General Inquiry form.

To learn more about the ACC Biotechnology Program please take a moment to view the video and browse the pages below:

Link:
ACC Biotechnology Department

This book is meant for students and professionals who are looking for reference on different areas in this field, to bring a new student or new hire up to speed.

A scientific revolution less than 20 years old that has already changing the foods we eat and react to the environment.

To bring out the best in nature.

Farmers and bakers were the pioneers of the biotech. Remember Grandma's freshly baked bread? How Grandpa kept the seeds of those really big pepper or tomatoes? Your grandparents were practicing biotechnology. Maybe you still do the same, that is the basis of biotechnology.

Defining "Biotechnology"

The application of the principles of engineering and the use of technology in the field of life sciences-bioengineering.

1 The use of living things to make products.2 The study, application and control of a biological processes. 3 The application of any of the above or derivatives thereof, to make or modify products or processes for specifically defined uses.

The use of microorganisms (such as bacteria or yeasts) or biological substances (such as enzymes) to perform specific industrial or manufacturing processes. Applications include the production of certain drugs, synthetic hormones, and bulk foodstuffs, as well as the bioconversion of organic waste and the cleanup of oil spills.

Cloning, genetic manipulation, cell fusion, and mutation.

Modifying the genetic material of organisms directly and with increasing precision, has enabled the transfer of genes between extremely diverse organisms, in combinations unlikely to occur by non-technological means, allowing speedier and more specific results.

Essentially, doing "more and faster" building on what we have known and done for centuries and going beyond.

Life- Defined as:

Products

Good laboratory practice for nonclinical laboratory studies:

http://www.access.gpo.gov/nara/cfr/waisidx_02/21cfr58_02.html

Title 21 Code of Federal Regulations (21 CFR Part 11)Electronic Records; Electronic Signatures

http://www.fda.gov/ora/compliance_ref/part11/

Part 210 - current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; general

Part 211 - current good manufacturing practice for finished pharmaceuticals

http://www.fda.gov/cder/dmpq/cgmpregs.htm

SOP's (Standard Operating Procedures)

Notebook

Documentation for Integrity and traceability

Keys to Successful Biotech products

Record Keeping

requirements

Development / Upstream / Downstream processes

Chemical

Yeast

Fungi

Mammalian Cells

Fermentation?

ExpensiveLabor intensiveOpen EndedTime Consuming

Raw MaterialsBatch to Batch variationsTransportation costsStorage

CompositionGrowth kineticsYieldSeed Bank

Original Stored Cells

Used in actual fermentation

The Biotech Technician must be a person possessing skills with ability to solve problems and meet the customer in such a way that the translations of what is possible can be made clear. They have to maintain a notebook, one that can be read by someone else. Present results in a clear manner, and work with others to meet objectives.

A technician must use the tools of the trade not unlike any other trade, we are farmers but our herd is tiny tiny wildlife. To take care of our herd we must measure certain aspects of their environment.

most accuratemore expensive piece of equipmentStore in bufferCheck for clogging

very coarse measurement of pH

The letters pH stand for "power of hydrogen"

The most abundant element in the universe is hydrogen, which makes up about 3/4 of all matter!

Stronger acids give up more protons, H+ (hydrogen ions); stronger bases give up more OH- (hydroxide ions). Neutral substances have an even balance of H+ and OH-, E.g. Pure (distilled) water.

>7 base -- 7 Neutral -- <7 Acid

Depending on your definition, an acid is a hydrogen ion or proton donator and a base is a hydrogen ion acceptor, hydroxide ion donator, or electron acceptor.

Acids produce H+ ions in aqueous solutions, whereas bases produce OH- ions in aqueous solutions

pH electrode compared to a battery

Store in buffer not H2O

Mercury tubeGood for metals and biologicals and up to 80 degrees C

The common Silver-Silver Chloride reference electrode used with most combination pH electrodes has a Potassium Chloride salt-bridge which is saturated with Silver Chloride.

Works well in most samples, but not in biological samples containing proteins or related materials

Span errorDifference b/w perfect and actual pH Electrode at 25C produces 59.12 mV/pH unit

Offset error

signal @ pH 7.0 @ 25 C is 0 mV

Three point calibration

Calibrate W/I range you going to use

Chemist use buffers to moderate the pH of a reaction.Buffers stabilize a solution at a specific pH value.Resist pH change when small amounts of acid or alkali are added.

KPO4

KPO4 buffer is highly recommended for most P450 assays (microsomal or recombinant enzymes) with the exception of CYP 2C9 and 2A6 where a Tris buffer system is more appropriate.

TRIS buffer

TRIS buffers are used by biochemists to control pH in the physiological range (about 7 to 8 pH) because phosphates cause undesirable side reactions with the biological substances in their test samples.

"Good" buffers

These buffers were well received by the research community because "Good" buffers are nontoxic, easy to purify and their pKa is typically between 6.0 and 8.0, the range at which most biological reactions occur.

The "Good" buffers also feature minimal penetration of membranes, minimal absorbance in the 240-700 nm range and minimal effects due to salt, concentration or temperature.

pKa = dissociation constant

In chemistry and biochemistry, a dissociation constant or an ionization constant is a specific type of equilibrium constant used for dissociation (ionization) reactions.Dissociation in chemistry and biochemistry is a general process in which complexes, molecules, or salts separate or split into smaller molecules, ions, or radicals, usually in a reversible manner. Dissociation is the opposite of association and recombination.

Problems

A gelatinous material derived from certain marine algae.

Two types:

Components required for preparing a minimal agar

LB (Luria-Bertani) Media

contains blood cells from an animal (e.g. a sheep). Most bacteria will grow on this medium

This contains lysed blood cells, and is used for growing fastidious (fussy) respiratory bacteria.

Purpose Mannitol salt agar is both a selective and differential growth medium.

Inhibits Gram+MacConkey

This type of agar is used since it is one of the most forgiving media available - it is hard to contaminate, and E. coli usually grow up as red colonies.

(Almost all spore forming bacteria are Gram-positive, but these cannot grow on MacConkey agar because of the detergent in it (bile salts), and very few Gram-negative bacteria can tolerate either the initial dryness of the plates, or the boiling temperatures needed to make the MacConkey agar. Also, while fungal spores can tolerate the dryness, they cannot tolerate the boiling.)

This is an agar upon which only Gram-negative bacteria can grow

Starch

An agar plate is a sterile Petri dish that contains agar plus nutrients, and is used to culture bacteria or fungi.

contains the antibiotic neomycin.

Used for fungi. It contains gentamicin and has a low pH that will kill most bacteria.

+ Complex+ pH 7.2

Common UV/ VIS spectrophotometers Following is a list of commonly used spectrophotometers: GeneSys 20 HP8452A Diode Array Spectronic 20

Ultraviolet-Visible spectroscopy or Ultraviolet-Visible spectrophotometry (UV/ VIS) involves the spectroscopy of photons (spectrophotometry). It uses light in the visible and adjacent near ultraviolet (UV) and near infrared (NIR) ranges. In this region of energy space molecules undergo electronic transitions.

A=elc

There are different types of Sterilization techniques. Some of them are 1. Physical sterilization 2. Chemical sterilization

Under Physical sterilization a) Heatb) Filtration c) Ionising Radiation etc.,In Heat sterilization i. Temperature above 100 Cii. Temperature at 100 Ciii. Temperature below 100 C.

i. Temperature above 100 CThere are two methods involved in it a. Moisture heat sterilizationb. Dry heat sterilization

Using a balanceCalibration / documentation

Gel electrophoresis is a method that separates macromolecules-either nucleic acids or proteins-on the basis of size, electric charge, and other physical properties. Researchers can typically control the charge at the top and bottom of the gel. DNA is negatively charged so to run it through the gel, the top would have to be set to - and the bottom to +.

materials

agarose

Agarose is a natural colloid extracted from sea weedIt is very fragile and easily destroyed by handlingAgarose gels have very large "pore" size and are used primarily to separate very large molecules with a molecular mass greater than 200 kDaltonsAgarose gels can be processed faster than polyacrylamide gels, but their resolution is inferior.

Agarose is a linear polysaccharide (average molecular mas about 12,000) made up of the basic repeat unit agarobiose, which comprises alternating units of galactose and 3,6-anhydrogalactose. Agarose is usually used at concentrations between 1% and 3%. Agarose is a chain of sugar molecules, and is extracted from seaweed.

Perhaps you have seen the terms TBE or TAE.

These are names of two commonly used buffers in electrophoresis.

The "T" stands for Tris, a chemical which helps maintain a consistent pH of the solution.

The "E" stands for EDTA, which itself is another anacronym. EDTA chelates (gobbles up) divalent cations like magnesium. This is important because most nucleases require divalent cations for activity, and you certainly wouldn't want any stray nucleases degrading your sample while it's running through the gel, would you?

See original here:
Biotechnology - Wikibooks, open books for an open world

Gene editing and stem cell research have allowed for alternative rodent reproduction

4 minutes ago Dina Fine Maron

Draft guidelines permit gene-editing tools for research into early human development, but would discourage manipulation of embryos for reproduction

October 3, 2018 David Cyranoski and Nature magazine

James P. Allison and Tasuku Honjo share the Nobel Prize for their work on harnessing the cancer patient's own immune system to destroy tumors.

October 1, 2018 Steve Mirsky

Researchers at the Mount Sinai Diabetes Center have already developed an artificial pancreas. Next, a drug that could regenerate pancreatic cells in the body.

September 12, 2018

Immunologist James Allison has spent over thirty years studying T cells and developing strategies for cancer immunotherapy. Now, hes looking at new ways to unleash the immune system to eradicate cancer.

September 12, 2018

Interview: Joan Argetsinger Steitz weighs in on #MeToo and working with James Watson

September 11, 2018 Dina Fine Maron

New device gives an amputee the ability to feel the location of his foot

August 9, 2018 Simon Makin

As Ebola outbreaks occur again and again, the scramble for answers and medications is ongoing

August 6, 2018

Shutting down an overactive enzyme could become a general treatment, rather than one solely intended for the few who inherit a mutated Parkinsons gene

August 6, 2018 Emily Willingham

A flurry of recent findings highlighta contentious question in this area

July 16, 2018 Sharon Begley and STAT

A next-generation cochlear implant might allow the hearing-impaired to listen to music and cope with noise

July 16, 2018 Simon Makin

Activating the reward system boosts anti-tumor immunity in mice

July 13, 2018 Esther Landhuis

The controversy over how many genes are contained in the human genome continues to simmer

June 19, 2018 Cassandra Willyard and Nature magazine

The preliminary findings raise questions about one of the ways this tech edits genomes

June 12, 2018 Sharon Begley and STAT

Three patients in Japan will receive the experimental therapy in the next year

May 30, 2018 David Cyranoski and Nature magazine

The swallowable device looks promising in pigs

May 24, 2018 Andrew Joseph and STAT

A new technique could replace the need for human embryos in some lab experiments

May 24, 2018 Sara Reardon and Nature magazine

Racing pigeons is big businessand doping is common. Now scientists have devised a way to detect doping in the avian athletes. Christopher Intagliata reports.

May 15, 2018 Christopher Intagliata

Researchers are intent on decoding body-brain nerve signals to diagnose ailments

May 10, 2018 Tim Hornyak

Chinas move is expected to complement other countriesrelated initiatives

April 6, 2018 David Cyranoski and Nature magazine

Discover world-changing science. Explore our digital archive back to 1845, including articles by more than 150 Nobel Prize winners.

View original post here:
Biotech - Scientific American

By Murray McLaughlin

SARNIA, Ont. /Troy Media/ - It took until 1800 for the world population to reach one billion people. The second billion was reached in only 130 years (1930), the third billion in less than 30 years (1959), the fourth billion in 15 years (1974) and the fifth billion in only 13 years (1987).

During the 20th century alone, the global population grew from 1.6 billion to over six billion people.

In 1970, there were roughly half as many people in the world as there are today.

In The Population Bomb (1968), Paul Ehrlich writes: "The world, especially the developing world, is rapidly running out of food ... in fact the battle to feed humanity is already lost in the sense that we will not be able to prevent large-scale famine in the next decade or so."

How was this global starvation catastrophe averted?

One element high on the list is innovation. Crop production science and innovation led to new technologies that produce more per acre and more per crop inputs.

Dr. Norman Borlaug was an American agronomist known as "the father of the Green Revolution." Borlaug developed new varieties of wheat that were planted around the world and had tremendous yield responses. His approach was adopted by other scientists to improve other crops. He was awarded the Nobel Peace Prize in 1970 for his contributions to world peace through increasing food supply. Borlaug is often credited with saving over a billion people from starvation.

With new technologies based on Borlaug's research, the successes continue. Biotechnology is a new set of tools that enhance crop breeding for new plant traits. Products from biotechnology have shown tremendous improvement since first provided to farmers in 1995. Biotech-bred crops allow farmers to reduce pesticide use, and improve quality and yields with reduced input costs. Biotech-enhanced crops are now grown by 18 million farmers, most of them in developing countries.

In Canada, corn, soybeans and canola are grown using biotechnology (often referred to as genetically-modified organisms or GMOs). All are designed to reduce pesticide use while improving yields. In 1940, corn varieties yielded 25 to 40 bushels per acre. Now, with hybrids and biotechnology, yields are typically 150 to 200 bushels per acre.

GMOs have helped Canadian farmers manage production costs, increase yields and provide safe, nutritious food to the world's consumers. There is tremendous experience and knowledge about the safety and benefits of GMO crops, based on years of development, testing and production.

The predictions of major hazards, by critics of GMO, have not materialized. GMO crops have played a vital role in improving world agricultural food production per capita. And this will be an ongoing need as the world's population heads to 10 billion people later this century.

Biotechnology in agriculture production should be embraced the same way we have embraced innovation in medicine, transportation, communication and any number of other sectors. Biotechnology will continue to help reduce global poverty.

We need more people like Borlaug. Through research, science and innovation, he helped ensure we have the necessary tools for a healthy future. Biotechnology will be an important part of that future.

Dr. Murray McLaughlin is an adviser to and former executive director of Bioindustrial Innovation Canada, based in Sarnia, Ont., and a former Saskatchewan deputy minister of agriculture.

Excerpt from:
Agricultural biotechnology crucial for feeding world population - Clearwater Times

Sessions and Tracks

Track 1: Pharmaceutical Biotechnology

Pharmaceutical Biotechnology is the science that covers all technologies required for producing, manufacturing and registration of biological drugs. Pharmaceutical companies use biotechnology for manufacturing drugs, pharmacogenomics, gene therapy, and genetic testing. Biotech companies make biotechnology products by manipulating and modifying organisms, usually at molecular level. Pharmaceutical Biotechnology is an increasingly important area of science and technology. It contributes in design and delivery of new therapeutic drugs, diagnostic agents for medical tests, and in gene therapy for correcting the medical symptoms of hereditary diseases. The Pharmaceutical Biotechnology is widely spread, ranging from many ethical issues to changes in healthcare practices and a significant contribution to the development of national economy. Euro Biotechnology 2018 will focus on Biopharmaceuticals Discovery, Biopharmaceutical Regulations and Validations, Biologics and Biosimilars and Clinical Research/Clinical trials.

Related: Pharmaceutical Biotechnology Conferences | Biopharmaceutical Conferences | Molecular Biology Conferences

9th Molecular Immunology & Immunogenetics Congress, March 08-09, 2018, London, UK; World Congress and Expo on Applied Microbiology, November 29-December 01, 2017, Madrid, Spain; 11th International Conference on Tissue Engineering & Regenerative Medicine, October 18-20, 2018, Rome, Italy; 4th International Conference on Systems and Synthetic Biology, June 11-12, 2018 Rome, Italy; 4th International Conference on Bioscience ,July 2-3, 2018, Vienna, Austria; 20th Global congress on Biotechnology, March 5-7, 2018 London, UK; 10th International Conference on Genomics and Molecular Biology, May 21-23, 2018 Barcelona, Spain; 16th International Pharmaceutical Microbiology and Biotechnology Conference, May 21-23, 2018, Vienna, Austria; 7th International Conference and Exhibition on Cell and Gene Therapy, March 15-17, 2018, London, UK; 6th International Conference on Integrative Biology, May 21-23, 2018, Barcelona, Spain; Synaptic and Structural Plasticity, 26 Aug - 02 Sep 2017, Siena, Italy; 23rd Annual International Partnering Conference, Nov 06-08, 2017, Berlin, Germany; 13th Annual Quality in Pharma & Biotech, Sep 28 29,2017, Hanover, Germany; InnovateBopitech2017 Biotechnology & Industrial Revolution, November 27-28, 2017, Brisbane, Australia; Bioinformatics - Applications in Human Genomics and Precision Medicine Congress, 09 Oct 2017 - 10 Oct 2017, London, United Kingdom; Neuroepigenetics and Epitranscriptomics, Aug 19-26, 2017, Siena, Italy; International Conference on Biotechnology and Bioengineering, Sep 28- 30, 2017, Offenburg, Germany; The European Forum for Industrial Biotechnology and the Bioeconomy, October 19-20 2017, Brussels, Belgium; International Conference On Nanomedicine And Nanobiotechnology, September 25-27, 2017, Barcelona, Spain.

Related Societies:

Europe:

International Society for Pharmaceutical Engineering, The Pharmaceutical Society of Ireland, Manchester University Pharmaceutical Society, Society for Chemical Engineering Biotechnology, Pharmaceutical Society of Australia, Spanish Society of Biotechnology, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society of Microbial Ecology and Disease, Romanian Society of Medical Mycology and Mycotoxicology, Russian Medical Society, Society for Engineering in Agriculture.

USA:

Society for Biological Engineering, The Protein Society, Mexican Society for Biotechnology and Bioengineering, National Society of Agriculture, Pharmaceutical Marketing Society

Asia:

Society for Industrial Microbiology and Biotechnology (SIMB), The Pharmaceutical Society of Korea, Korean Society of Food Science And Technology, Indian Society of Nano science And Nanotechnology, Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Iran Society for Cell Biology, Israel Societies for Experimental Biology.

Track 2: Medical and Healthcare Biotechnology

Medicine is by means that of biotechnology techniques most in identification and treating dissimilar diseases. It additionally provides opportunity for the population to defend themselves from dangerous diseases. The pasture of biotechnology, genetic engineering, has introduced techniques like gene therapy, recombinant DNA technology and polymerase chain retort which employ genes and DNA molecules to make a diagnosis diseases and put in new and strong genes in the body which put back the injured cells. There are some applications of biotechnology which are live their part in the turf of medicine and giving good results.

Related: Medical Biotechnology Conferences | Genetic Engineering Conferences | Healthcare Conferences

6th International Conference on Integrative Biology, May 21-23, 2018, Barcelona, Spain; 7th International Conference and Exhibition on Cell and Gene Therapy, March 15-17, 2018, London, UK; Stem Cell Conferences 2018 USA; 16th International Pharmaceutical Microbiology and Biotechnology Conference, May 21-23, 2018, Vienna, Austria; Regenerative Medicine Conferences USA ; 10th International Conference on Genomics and Molecular Biology, May 21-23, 2018 Barcelona, Spain; 20th Global congress on Biotechnology, March 5-7, 2018 London, UK; 4th International Conference on Bioscience, July 2-3, 2018, Vienna, Austria; 4th International Conference on Systems and Synthetic Biology, June 11-12, 2018 Rome, Italy: 11th International Conference on Tissue Engineering & Regenerative Medicine, October 18-20, 2018, Rome, Italy; 9th Molecular Immunology & Immunogenetics Congress, March 08-09, 2017, London, UK; World Congress and Expo on Applied Microbiology, November 29-December 01, 2017, Madrid, Spain; Bioinformatics - Applications in Human Genomics and Precision Medicine Congress, 09 Oct 2017 - 10 Oct 2017, London, United Kingdom; InnovateBopitech2017 Biotechnology & Industrial Revolution, November 27-28, 2017, Brisbane, Australia; 13th Annual Quality in Pharma & Biotech, Sep 28 29,2017, Hanover, Germany; 23rd Annual International Partnering Conference, Nov 06-08, 2017, Berlin, Germany; Synaptic and Structural Plasticity, 26 Aug - 02 Sep 2017, Siena, Italy; International Conference On Nanomedicine And Nanobiotechnology, September 25-27, 2017, Barcelona, Spain; The European Forum for Industrial Biotechnology and the Bioeconomy, October 19-20 2017, Brussels, Belgium; ICBB 2017 6th International Conference on Biotechnology and Bioengineering, Sep 28- 30, 2017, Offenburg, Germany; Neuroepigenetics and Epitranscriptomics, Aug 19-26, 2017, Siena, Italy.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia.

USA:

The Protein Society, Mexican Society for Biotechnology and Bioengineering, Pharmaceutical Marketing Society, National Society of Agriculture, Society for Biological Engineering.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Japanese Society for Quantitative Biology, Society for Biotechnology.

Track 4: Biomaterials

A biomaterial is any substance that has been designed to act with biological systems for a medical purpose - either a therapeutic (treat, augment, repair or replace a tissue perform of the body) or a diagnostic one. it's experienced steady and robust growth over its history, with several firms finance massive amounts of cash into the event of latest product. Biomaterials science encompasses components of medication, biology, chemistry, tissue engineering and materials science. They're usually used and/or custom-made for a medical application, and therefore contains whole or a part of a living structure or medical specialty device that performs, augments, or replaces a natural perform. Such functions are also comparatively passive, like being employed for a heart valve, or could also be bioactive with a additional interactive practicality like hydroxy-apatite coated hip implants. Biomaterials also are used on a daily basis in dental applications, surgery, and drug delivery.

Related: Biomaterials Conferences | Biotechnology Conferences | Biomaterials and Tissue Engineering Conferences

6th International Conference on Integrative Biology, May 21-23, 2018, Barcelona, Spain; Cell Therapy Conferences ; 7th International Conference and Exhibition on Cell and Gene Therapy, March 15-17, 2018, London, UK; 16th International Pharmaceutical Microbiology and Biotechnology Conference, May 21-23, 2018, Vienna, Austria; Biotechnology Conferences USA 2018; 10th International Conference on Genomics and Molecular Biology, May 21-23, 2018 Barcelona, Spain; 20th Global congress on Biotechnology, March 5-7, 2018 London, UK; Biotechnology Conferences Asia 2018; 4th International Conference on Bioscience, July 2-3, 2018, Vienna, Austria; 4th International Conference on Systems and Synthetic Biology, June 11-12, 2018 Rome, Italy: 11th International Conference on Tissue Engineering & Regenerative Medicine, October 18-20, 2018, Rome, Italy; 9th Molecular Immunology & Immunogenetics Congress, March 08-09, 2017, London, UK; World Congress and Expo on Applied Microbiology, November 29-December 01, 2017, Madrid, Spain; Bioinformatics - Applications in Human Genomics and Precision Medicine Congress, 09 Oct 2017 - 10 Oct 2017, London, United Kingdom; InnovateBopitech2017 Biotechnology & Industrial Revolution, November 27-28, 2017, Brisbane, Australia; 13th Annual Quality in Pharma & Biotech, Sep 28 29,2017, Hanover, Germany; 23rd Annual International Partnering Conference, Nov 06-08, 2017, Berlin, Germany; Synaptic and Structural Plasticity, 26 Aug - 02 Sep 2017, Siena, Italy; International Conference On Nanomedicine And Nanobiotechnology, September 25-27, 2017, Barcelona, Spain; The European Forum for Industrial Biotechnology and the Bioeconomy, October 19-20 2017, Brussels, Belgium; ICBB 2017 6th International Conference on Biotechnology and Bioengineering, Sep 28-30, 2017, Offenburg, Germany; Neuroepigenetics and Epitranscriptomics, Aug 19-26, 2017, Siena, Italy.

Related Societies:

Europe:

Spanish Society of Biotechnology, Society for Chemical Engineering Biotechnology, The Pharmaceutical Society of Ireland, Romanian Society of Medical Mycology and Mycotoxicology, Russian Medical Society, Society for Engineering in Agriculture, New Zealand Plant Protection Society, Society of Microbial Ecology and Disease, European Society for Precision Engineering and Nanotechnology, International Society for Pharmaceutical Engineering, Manchester University Pharmaceutical Society, Pharmaceutical Society of Australia, Italian Society of Biochemistry and Molecular Biology

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,

Asia:

Tanta Pharmaceutical Scientific Society (TPSS), Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Iran Society for Cell Biology, Israel Societies for Experimental Biology. Society for Industrial Microbiology and Biotechnology (SIMB), The Pharmaceutical Society of Korea, Korean Society of Food Science And Technology, Indian Society of Nano science And Nanotechnology, Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,

Track 5: Industrial and Manufacturing Biotechnology

Industrial biotechnology is that the application of biotechnology for industrial functions, together with industrial fermentation. The observe of exploitation cells like micro-organisms, or elements of cells like enzymes, to come up with industrially helpful product in sectors like chemicals, food and feed, detergents, paper and pulp, textiles and biofuels. Industrial Biotechnology offers a premier forum bridging basic analysis and R&D with later-stage development for sustainable bio based mostly industrial and environmental applications.

Related: Industrial Biotechnology Conferences | Biotechnology Conferences | Industrial Biology

4th International Conference on Systems and Synthetic Biology, June 11-12, 2018 Rome, Italy: 16th International Pharmaceutical Microbiology and Biotechnology Conference, May 21-23, 2018, Vienna, Austria; 7th International Conference and Exhibition on Cell and Gene Therapy, March 15-17, 2018, London, UK; 4th International Conference on Bioscience, July 2-3, 2018, Vienna, Austria; World Congress and Expo on Applied Microbiology, November 29-December 01, 2017, Madrid, Spain; 9th Molecular Immunology & Immunogenetics Congress, March 08-09, 2017, London, UK; 20th Global congress on Biotechnology, March 5-7, 2018 London, UK; 6th International Conference on Integrative Biology, May 21-23, 2018, Barcelona, Spain; 10th International Conference on Genomics and Molecular Biology, May 21-23, 2018 Barcelona, Spain; 11th International Conference on Tissue Engineering & Regenerative Medicine, October 18-20, 2018, Rome, Italy; Synaptic and Structural Plasticity, 26 Aug - 02 Sep 2017, Siena, Italy; 23rd Annual International Partnering Conference, Nov 06-08, 2017, Berlin, Germany; 13th Annual Quality in Pharma & Biotech, Sep 28 29,2017, Hanover, Germany; InnovateBopitech2017 Biotechnology & Industrial Revolution, November 27-28, 2017, Brisbane, Australia; Bioinformatics - Applications in Human Genomics and Precision Medicine Congress, 09 Oct 2017 - 10 Oct 2017, London, United Kingdom; Neuroepigenetics and Epitranscriptomics, Aug 19-26, 2017, Siena, Italy; ICBB 2017 6th International Conference on Biotechnology and Bioengineering, Sep 28- 30 2017 Offenburg, Germany; The European Forum for Industrial Biotechnology and the Bioeconomy, October 19-20 2017, Brussels, Belgium; International Conference On Nanomedicine And Nanobiotechnology, September 25-27, 2017, Barcelona, Spain.

Related Societies:

Europe:

Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Pharmaceutical Society of Australia, Spanish Society of Biotechnology, Society for Chemical Engineering Biotechnology, Manchester University Pharmaceutical Society, The Pharmaceutical Society of Ireland, International Society for Pharmaceutical Engineering, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, Russian Medical Society, Society for Engineering in Agriculture.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,

Asia:

Society for Industrial Microbiology and Biotechnology (SIMB), The Pharmaceutical Society of Korea, Korean Society of Food Science And Technology, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Iran Society for Cell Biology, Israel Societies for Experimental Biology. Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,

Track 7: Bioprocess and Fermentation Technology

A bioprocess is a specific process that uses complete living cells or their components to obtain desired products. Transport of energy and mass is fundamental to many biological and environmental processes. Areas, from food processing to thermal design of building to biomedical devices to pollution control and global warming, require knowledge of how energy and mass can be transported through materials.

Related: Industrial Biotechnology Conferences | Biotechnology Conferences | Industrial Biology

4th International Conference on Systems and Synthetic Biology, June 11-12, 2018 Rome, Italy: 16th International Pharmaceutical Microbiology and Biotechnology Conference, May 21-23, 2018, Vienna, Austria; 7th International Conference and Exhibition on Cell and Gene Therapy, March 15-17, 2018, London, UK; 4th International Conference on Bioscience, July 2-3, 2018, Vienna, Austria; World Congress and Expo on Applied Microbiology, November 29-December 01, 2017, Madrid, Spain; 9th Molecular Immunology & Immunogenetics Congress, March 08-09, 2017, London, UK; 20th Global congress on Biotechnology, March 5-7, 2018 London, UK; 6th International Conference on Integrative Biology, May 21-23, 2018, Barcelona, Spain; 10th International Conference on Genomics and Molecular Biology, May 21-23, 2018 Barcelona, Spain; 11th International Conference on Tissue Engineering & Regenerative Medicine, October 18-20, 2018, Rome, Italy; Synaptic and Structural Plasticity, 26 Aug - 02 Sep 2017, Siena, Italy; 23rd Annual International Partnering Conference, Nov 06-08, 2017, Berlin, Germany; 13th Annual Quality in Pharma & Biotech, Sep 28 29,2017, Hanover, Germany; InnovateBopitech2017 Biotechnology & Industrial Revolution, November 27-28, 2017, Brisbane, Australia; Bioinformatics - Applications in Human Genomics and Precision Medicine Congress, 09 Oct 2017 - 10 Oct 2017, London, United Kingdom; Neuroepigenetics and Epitranscriptomics, Aug 19-26, 2017, Siena, Italy; ICBB 2017 6th International Conference on Biotechnology and Bioengineering, Sep 28- 30 2017 Offenburg, Germany; The European Forum for Industrial Biotechnology and the Bioeconomy, October 19-20 2017, Brussels, Belgium; International Conference On Nanomedicine And Nanobiotechnology, September 25-27, 2017, Barcelona, Spain.

Related Societies:

Europe:

Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Pharmaceutical Society of Australia, Spanish Society of Biotechnology, Society for Chemical Engineering Biotechnology, Manchester University Pharmaceutical Society, The Pharmaceutical Society of Ireland, International Society for Pharmaceutical Engineering, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, Russian Medical Society, Society for Engineering in Agriculture.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,

Asia:

Society for Industrial Microbiology and Biotechnology (SIMB), The Pharmaceutical Society of Korea, Korean Society of Food Science And Technology, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Iran Society for Cell Biology, Israel Societies for Experimental Biology. Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology

Track 8: Nanobiotechnology

Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found in Nano biology involve applying Nano tools to relevant medical/biological problems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology.

Related : Nano Biotechnology Conferences | Molecular Biology Conferences | Nano Biology Conferences

9th Molecular Immunology & Immunogenetics Congress, March 08-09, 2017, London, UK; Cell Therapy Conferences ; World Congress and Expo on Applied Microbiology, November 29-December 01, 2017, Madrid, Spain; 11th International Conference on Tissue Engineering & Regenerative Medicine, October 18-20, 2018, Rome, Italy; Biotechnology Conferences USA 2018; 4th International Conference on Systems and Synthetic Biology, June 11-12, 2018 Rome, Italy; Biotechnology Conferences Asia 2018; 4th International Conference on Bioscience, July 2-3, 2018, Vienna, Austria; 20th Global congress on Biotechnology, March 5-7, 2018 London, UK; 10th International Conference on Genomics and Molecular Biology, May 21-23, 2018 Barcelona, Spain; 16th International Pharmaceutical Microbiology and Biotechnology Conference, May 21-23, 2018, Vienna, Austria; 7th International Conference and Exhibition on Cell and Gene Therapy, March 15-17, 2018, London, UK; 6th International Conference on Integrative Biology, May 21-23, 2018, Barcelona, Spain; Synaptic and Structural Plasticity, 26 Aug - 02 Sep 2017, Siena, Italy; 23rd Annual International Partnering Conference, Nov 06-08, 2017, Berlin, Germany; 13th Annual Quality in Pharma & Biotech, Sep 28 29,2017, Hanover, Germany; InnovateBopitech2017 Biotechnology & Industrial Revolution, November 27-28, 2017, Brisbane, Australia; Bioinformatics - Applications in Human Genomics and Precision Medicine Congress, 09 Oct 2017 - 10 Oct 2017, London, United Kingdom; Neuroepigenetics and Epitranscriptomics, Aug 19-26, 2017, Siena, Italy; 6th International Conference on Biotechnology and Bioengineering, Sep 28- 30 Sep ,2017, Offenburg, Germany; The European Forum for Industrial Biotechnology and the Bioeconomy, October 19-20 2017, Brussels, Belgium; International Conference On Nanomedicine And Nanobiotechnology, September 25-27, 2017, Barcelona, Spain.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,

Asia:

Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Iran Society for Cell Biology, Israel Societies for Experimental Biology. Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology, Society for Industrial Microbiology and Biotechnology (SIMB), The Pharmaceutical Society of Korea, Korean Society of Food Science And Technology, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS),

Track 9: Biotechnology Applications

Biotechnology has application in four major industrial areas, including health care (medical), crop production and agriculture, nonfood (industrial) uses of crops and other products (e.g. biodegradable plastics, vegetable oil, biofuels), and environmental uses. Applied Microbiology and Biotechnology focusses on prokaryotic or eukaryotic cells, relevant enzymes and proteins, applied genetics and molecular biotechnology, genomics and proteomics, applied microbial and cell physiology, environmental biotechnology, process and products and more.

Related : Applied Biotechnology Conferences | Applied Microbiology Conferences | Molecular Biotechnology Conferences

9th Molecular Immunology & Immunogenetics Congress, March 08-09, 2017, London, UK; 4th International Conference on Systems and Synthetic Biology, June 11-12, 2018 Rome, Italy: Biotechnology Conferences Middle East 2018; 20th Global congress on Biotechnology, March 5-7, 2018 London, UK; 16th International Pharmaceutical Microbiology and Biotechnology Conference, May 21-23, 2018, Vienna, Austria; Biotechnology Conferences Canada 2018; 6th International Conference on Integrative Biology, May 21-23, 2018, Barcelona, Spain; Biotechnology Conferences Japan 2018; 7th International Conference and Exhibition on Cell and Gene Therapy, March 15-17, 2018, London, UK; 10th International Conference on Genomics and Molecular Biology, May 21-23, 2018 Barcelona, Spain; 4th International Conference on Bioscience, July 2-3, 2018, Vienna, Austria; 11th International Conference on Tissue Engineering & Regenerative Medicine, October 18-20, 2018, Rome, Italy, World Congress and Expo on Applied Microbiology, November 29-December 01, 2017, Madrid, Spain; InnovateBopitech2017 Biotechnology & Industrial Revolution, November 27-28, 2017, Brisbane, Australia; 13th Annual Quality in Pharma & Biotech, Sep 28 29,2017, Hanover, Germany; BIO-Europe 2017 - 23rd Annual International Partnering Conference, Nov 06-08, 2017, Berlin, Germany; Synaptic and Structural Plasticity, 26 Aug - 02 Sep 2017, Siena, Italy; International Conference On Nanomedicine And Nanobiotechnology, September 25-27, 2017, Barcelona, Spain; The European Forum for Industrial Biotechnology and the Bioeconomy, October 19-20 2017, Brussels, Belgium; 6th International Conference on Biotechnology and Bioengineering, Sep 28- 30 2017 Offenburg, Germany; Neuroepigenetics and Epitranscriptomics, Aug 19-26, 2017, Siena, Italy, Bioinformatics - Applications in Human Genomics and Precision Medicine Congress, 09 Oct 2017 - 10 Oct 2017, London, United Kingdom

Related Societies:

Europe:

Spanish Society of Biotechnology, Society for Chemical Engineering Biotechnology, The Pharmaceutical Society of Ireland, Romanian Society of Medical Mycology and Mycotoxicology, Russian Medical Society, Society for Engineering in Agriculture, New Zealand Plant Protection Society, Society of Microbial Ecology and Disease, European Society for Precision Engineering and Nanotechnology, International Society for Pharmaceutical Engineering, Manchester University Pharmaceutical Society, Pharmaceutical Society of Australia, Italian Society of Biochemistry and Molecular Biology

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,

Asia:

The Pharmaceutical Society of Korea, Korean Society of Food Science And Technology, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Iran Society for Cell Biology, Israel Societies for Experimental Biology. Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology, Society for Industrial Microbiology and Biotechnology (SIMB)

Track 10: Biotechnology and Intellectual Property Rights (IPR)

Biotechnology is a field where technology advances rapidly but returns on investments may be slow. For this reason, it is important for public research organisations and enterprises to protect the innovation that they generate with Intellectual Property Rights (IPR), which provide a basis for return on investment in research and development, by granting monopoly rights for a certain period of time to their owners. The IP created by biotechnology companies that can take a number of different forms, consisting of vaccines, seeds, plants, medical devices and software, but also brands and domain names, among others. Most of these different assets may attract more than one form of IP protection. In the biotechnology sector the most relevant form of IP are patents, although other forms are also applicable and used in practice.

Related: Biotechnology Conferences |Genomic Conferences | Synthetic Biology Conferences

6th International Conference on Integrative Biology, May 21-23, 2018, Barcelona, Spain; Cell Therapy Conferences ; 7th International Conference and Exhibition on Cell and Gene Therapy, March 15-17, 2018, London, UK; 16th International Pharmaceutical Microbiology and Biotechnology Conference, May 21-23, 2018, Vienna, Austria; Biotechnology Conferences USA 2018; 10th International Conference on Genomics and Molecular Biology, May 21-23, 2018 Barcelona, Spain; 20th Global congress on Biotechnology, March 5-7, 2018 London, UK; Biotechnology Conferences Asia 2018; 4th International Conference on Bioscience, July 2-3, 2018, Vienna, Austria; 4th International Conference on Systems and Synthetic Biology, June 11-12, 2018 Rome, Italy: 11th International Conference on Tissue Engineering & Regenerative Medicine, October 18-20, 2018, Rome, Italy; 9th Molecular Immunology & Immunogenetics Congress, March 08-09, 2017, London, UK; World Congress and Expo on Applied Microbiology, November 29-December 01, 2017, Madrid, Spain; Bioinformatics - Applications in Human Genomics and Precision Medicine Congress, 09 Oct 2017 - 10 Oct 2017, London, United Kingdom; InnovateBopitech2017Biotechnology & Industrial Revolution, November 27-28, 2017, Brisbane, Australia; 13th Annual Quality in Pharma & Biotech, Sep 28 29,2017, Hanover, Germany; 23rd Annual International Partnering Conference, Nov 06-08, 2017, Berlin, Germany; Synaptic and Structural Plasticity, 26 Aug - 02 Sep 2017, Siena, Italy; International Conference On Nanomedicine And Nanobiotechnology, September 25-27, 2017, Barcelona, Spain; The European Forum for Industrial Biotechnology and the Bioeconomy, October 19-20 2017, Brussels, Belgium; ICBB 2017 6th International Conference on Biotechnology and Bioengineering, Sep 28- 30 Sep ,2017 Offenburg, Germany; Neuroepigenetics and Epitranscriptomics, Aug 19-26, 2017, Siena, Italy.

Related Societies:

Europe:

Spanish Society of Biotechnology, Society for Chemical Engineering Biotechnology, The Pharmaceutical Society of Ireland, Romanian Society of Medical Mycology and Mycotoxicology, Russian Medical Society, Society for Engineering in Agriculture, New Zealand Plant Protection Society, Society of Microbial Ecology and Disease, European Society for Precision Engineering and Nanotechnology, International Society for Pharmaceutical Engineering, Manchester University Pharmaceutical Society, Pharmaceutical Society of Australia, Italian Society of Biochemistry and Molecular Biology

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,

Asia:

Iran Society for Cell Biology, Israel Societies for Experimental Biology. Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology, Society for Industrial Microbiology and Biotechnology (SIMB), The Pharmaceutical Society of Korea, Korean Society of Food Science And Technology, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy,

Track 11: Biotechnology Entrepreneurship

Biotechnology products arise from successful biotech companies. Entrepreneurs start biotechnology companies for various reasons, but creating revolutionary products and tools that impact the lives of potentially millions of people is one of the fundamental reasons why all entrepreneurs start biotechnology companies. Certainly, biotech entrepreneurs hope to make truckloads of money by building successful companies with billions in revenue. But most biotech entrepreneurs have an altruistic streak fueling their persistence, which keeps them going through the hardships and challenges that would stop cold those just looking to make a quick buck. The main focus is laid on Strategic Alliances, Partnering Trends, Product Opportunities, Business Models and Strategies, Merger and Acquisitions, Licensing and Growth.

Related: Biotechnology Conferences |Genomic Conferences | Synthetic Biology Conferences

4th International Conference on Systems and Synthetic Biology, June 11-12, 2018 Rome, Italy: 16th International Pharmaceutical Microbiology and Biotechnology Conference, May 21-23, 2018, Vienna, Austria; Stem Cell Conferences 2018 Asia; 7th International Conference and Exhibition on Cell and Gene Therapy, March 15-17, 2018, London, UK; Regenerative Medicine Conferences ASIA; 4th International Conference on Bioscience, July 2-3, 2018, Vienna, Austria; World Congress and Expo on Applied Microbiology, November 29-December 01, 2017, Madrid, Spain; 9th Molecular Immunology & Immunogenetics Congress, March 08-09, 2017, London, UK; 20th Global congress on Biotechnology, March 5-7, 2018 London, UK; 6th International Conference on Integrative Biology, May 21-23, 2018, Barcelona, Spain; 10th International Conference on Genomics and Molecular Biology, May 21-23, 2018 Barcelona, Spain; 11th International Conference on Tissue Engineering & Regenerative Medicine, October 18-20, 2018, Rome, Italy; Synaptic and Structural Plasticity, 26 Aug - 02 Sep 2017, Siena, Italy; 23rd Annual International Partnering Conference, Nov 06-08, 2017, Berlin, Germany; 13th Annual Quality in Pharma & Biotech, Sep 28 29,2017, Hanover, Germany; InnovateBopitech2017 Biotechnology & Industrial Revolution, November 27-28, 2017, Brisbane, Australia; Bioinformatics - Applications in Human Genomics and Precision Medicine Congress, 09 Oct 2017 - 10 Oct 2017, London, United Kingdom; Neuroepigenetics and Epitranscriptomics, Aug 19-26, 2017, Siena, Italy; ICBB 2017 6th International Conference on Biotechnology and Bioengineering, Sep 28- 30 Sep ,2017 Offenburg, Germany; The European Forum for Industrial Biotechnology and the Bioeconomy, October 19-20 2017, Brussels, Belgium; International Conference On Nanomedicine And Nanobiotechnology, September 25-27, 2017, Barcelona, Spain.

Related Societies:

Europe:

Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Pharmaceutical Society of Australia, Spanish Society of Biotechnology, Society for Chemical Engineering Biotechnology, Manchester University Pharmaceutical Society, The Pharmaceutical Society of Ireland, International Society for Pharmaceutical Engineering, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, Russian Medical Society, Society for Engineering in Agriculture.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology.

Continue reading here:
European Biotechnology Conference | Biotechnology ...

FinSMEs (blog)

Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M FinSMEs (blog) Paris, France based Advent France Biotechnology has held the first close of Advent France Biotechnology Seed-Fund I, at 64.75m (USD68.5m). Supported in by the National Seed-Fund (Fonds National d'Amorage) managed by Bpifrance under the ...

Link:
Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M - FinSMEs (blog)

Markets Daily

7007 Shares in iShares NASDAQ Biotechnology Index (IBB) Acquired by David R. Rahn & Associates Inc. The Cerbat Gem iShares NASDAQ Biotechnology Index logo David R. Rahn & Associates Inc. acquired a new position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) during the first quarter, according to its most recent filing with the Securities and Exchange ... Oakwood Capital Management LLC CA Sells 200 Shares of iShares ...Markets Daily iShares NASDAQ Biotechnology Index (IBB) Shares Sold by Greystone Investment Management LLCBBNS Reviewing Indicator Levels for Ishares Nasdaq Biotechnology (IBB ...Sherwood Daily Transcript Daily -Sports Perspectives -Petro Global News 24 all 15 news articles »

The rest is here:
7007 Shares in iShares NASDAQ Biotechnology Index (IBB) Acquired by David R. Rahn & Associates Inc. - The Cerbat Gem

In our fast-moving world, biotech is at the forefront of developments but, by its very nature, it can provoke ethical and moral concerns.

The European Patent Office (EPO) has faced opposition in the past, for instance, over patents relating to processes for re-engineering genes, for use in medical research into cancer treatment. These processes could apply to various animals, including great apes and that became a magnet for criticism from animal rights campaigners.

The number of patent filings for biotechnology increased by 0.3 percent in 2016, to 5,744 making it the tenth largest sector in its field.

Youris.com spoke to Benoit Battistelli, President of the EPO, about the role of patent protection and how it can aid biotechnology innovation and the wider bioeconomy despite the obstacles faced by some.

Benoit Battistelli -Courtesy of EPO

How much of a focus is the bioeconomy for patents and what are some of the key developments? Biosciences play an important role in patent applications at the EPO, given the growing convergence of technologies, which is widely responsible for technical progress in a wide number of sectors. Such inventions are mainly found in industrial biotechnology, for instance, in the development of novel products such as new detergents, functional food or even new eco-friendly material in construction, such as pollution-eating concrete and self-healing concrete.

The area of clean energy production is also very important. For example, when it comes to using biomass as an energy source [editors note: In 2011, a Danish inventor won a European Inventor Award organised by the EPO for developing a system which increases the types of biomass fuels that can be used. Typically, biomass materials have to be dried before they can be used as fuel, but Jens Dall Bentzens furnace design can also burn materials with a moisture content of up to 60 percent. Hes since reported to have attracted interest from Europe and the US, selling the furnace to an American manufacturer, as well as building two others for use in Denmark].

Is the bioeconomy an increasing sector? Biotech is among our top ten technical fields and it has increased. At the end of the patent granting process, its about 50 percent on average that become a patent. Its only 26 or 27 percent in the case of biotech. Why? Because it is a very sensitive issue and we are applying the patentability criteria very rigorously. There are huge European capacities in biotech and we have seen that we must find a good balance between the regulatory constraints and the economic capacities that this sector represents.

The position of the EPO is very clear and simple. There is an EU directive concerning biotech, which we respect and which we have integrated in our own legal framework, the European Patent Convention. Then you have the interpretations of the Directive by the European Court of Justice and we adapt our practice to these judgements.

Overall, how complicated is it to obtain a patent, and is it expensive? I would not say that it is complicated, but it is a difficult process, because we always start from the basis thata patent is an exception to the principle of free trade, free industry, free competition. Globally, for around20 to 25,000 euros, you can obtain a patent as the EPO. For this amount, 5,000 euros are the EPO fees and the rest is the fees of those who helped to draft a patent and then discuss it with the patent office.

So, with a patent, you are giving the holderthe exclusive right of commercially exploiting his invention, for a certain period of time, amaximum 20 years.

This article is part of the communication of theProBIO project, a support action for KBBE projects which identifies research results to facilitate their uptake into the relevant sector.

youris.com provides its content to all media free of charge. We would appreciate if you could acknowledge youris.com as the source of the content.

Read more:
Biotechnology: navigating a minefield - Youris.com

CAMBRIDGE, Mass., April 12, 2017 /PRNewswire/ --ReadCoor, Inc. today announced that an article appearing in the April 2017 issue of Nature Biotechnology named the company among the 10 leading academic spinouts for 2016. Each year the journal identifies and features companies originating from academic institutions who have generated significant initial funding and who in the editors' assessment have demonstrated novel, potentially disruptive technology. In the words of the journal, "We believe these [ventures] represent some of the best science coming out of academia in 2016."

"It is a tremendous honor to be included in this group of amazing technologies and companies," said Shawn Marcell, ReadCoor co-founder and CEO. "The team at ReadCoor is excited to deliver on the promise this revolutionary platform holds."

The ReadCoor platform, called FISSEQ Fluorescent In-Situ Sequencing is the first application of in-situ spatial sequencing. ReadCoor was founded in 2014 by Richard Terry and George Church at the Harvard Wyss Institute, to bring Fluorescent In-Situ Sequencing into mainstream research use. Several key applications are being advanced including pathogen detection under a grant provided by the Bill & Melinda Gates Foundation, brain mapping or neural connectomics funded by IARPA, and drug development in areas such as central nervous system, neurodegenerative diseases, oncology, immunotherapy and gene therapy. Unlike traditional sequencing technologies, ReadCoor provides a method to pinpoint the precise locations of specific RNA molecules in intact tissue.

About ReadCoor

ReadCoor is leading the next generation of "omics" by delivering the first panomic spatial sequencing platform to researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is spearheading the charge with Fluorescent In-Situ Sequencing, a fundamental innovative technology that simultaneously integrates high throughput next generation sequencing, morphometric tissue analysis and three-dimensional spatial imaging. This uniquely powerful tool is the first and only implementation of "In-situ Sequencing" and will revolutionize the next phase in understanding the transcriptome, introducing vast new opportunities for important and meaningful clinical insights.

Contact Sam Inverso ReadCoor, Inc. Readcoor.com (617) 453-2660

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nature-biotechnology-features-readcoor-as-a-2016-leading-spinout-300438536.html

SOURCE ReadCoor, Inc.

http://www.readcoor.com

Read more from the original source:
Nature Biotechnology Features ReadCoor as a 2016 Leading Spinout - PR Newswire (press release)

[The following is the first part of anInformation Technology and Innovation Foundation report.]

New techniques for improving plants and animals promise to reshape virtually every aspect of the relationship between humans and our environment for the better. Safer and more sustainable crops have already made enormous contributions to the economy and the environment, and genetically improved livestock and companion animals are close behind. Discovery of more precise, predictable, and easily used techniques derived directly from nature is dramatically accelerating this progress. But fears of the new have led to calls in many nations for precautionary regulation, which risks stifling agricultural innovation without any showing of need or benefit. There is a better way. This report discusses proposals for updating policies and regulations for agricultural biotechnology products in the United States to ensure they safeguard

This report discusses proposals for updating policies and regulations for agricultural biotechnology products in the United States to ensure they safeguard public and environmental health and animal welfare without discouraging needed innovations. An authoritative review of 10 years worth of academic literature has found that the scientific research conducted so far has not detected any significant hazards directly connected with the use of [genetically engineered] crops. This experience is evidence that the time is long past due for significant regulatory rollback in this field around the world. Good advice has already been offered as to the best ways for updating these regulations. Not all of it has been followed yet, leaving numerous opportunities for improvement by the new administration. This report recommends the following reforms:

BACKGROUND The single biggest obstacle slowing the wider dissemination of the considerable benefits from agricultural biotechnology innovations is unwarranted regulatory burdens across the world. The disparity between the degree of hazard or risk associated with these innovations and the regulatory hurdles they must clear has widened everywhere over the past three decades from a gap to a chasm. This has happened even while experience has shown that early safety concerns were unfounded, and that the predictability and safety associated with these innovations has been shown to be unmatched by the products of any other production method.

What Is Agricultural Biotechnology and Why Should We Care? Innovations in agriculture are being delivered today through a host of different techniques referred to with a baffling array of labels: recombinant DNA, genetically modified organisms (GMOs), genetic modification (GM), gene editing, CRISPR, TALENs, Zinc Fingers, meganucleases, advanced breeding, new breeding technologies, precision agriculture, big data, remote sensing, and more. There is some overlap among these terms both vis--vis the subject matter they cover and the ways in which they are used, but misunderstanding is widespread, and scientific justification for some of these terms is lacking or altogether absent.

When scientifically nonsensical terms are used as the foundation of discriminatory regulations, without due regard for hazard or risk, the resulting policies do not advance the protection of public and environmental health. This is the case for any and all regulations that single out GM processes or GMOs for regulatory scrutiny. Scientists and policy mavens spent years examining these issues in the late 1970s and early 1980s. They reached consensus that the process of genetic modification tells regulators nothing useful about any possible hazards of the resulting product, or the risks associated with different levels of exposure; these require consideration of the final characteristics and qualities of a productits phenotype. To use an example from manufacturing, a products safety does not depend on how a chemical is made, but rather on its chemical composition and structure. The same is true for food, feed, fiber, and animal products. Yet, for ideological or political reasons unsupported by data or experience, many nations regulators have adopted explicitly process-based regulations. Even countries that have avoided this fundamental error have drifted in that direction through

Yet, for ideological or political reasons unsupported by data or experience, many nations regulators have adopted explicitly process-based regulations. Even countries that have avoided this fundamental error have drifted in that direction through uncritical implementation of otherwise less flawed regulations that slow ag-biotech innovation. These different developments have combined to create the gross disparity between and within nations regarding risk and regulatory burden as manifested in regulatory proposals we examine here.

GM Food Is Safe The foundation of confidence in the safety of agricultural products produced through biotechnology, no matter what breeding method was used, lies in a concept known as substantial equivalence. This is based on the work of an international expert group at the Organization for Economic Cooperation and Development (OECD), which published a series of landmark policy papers in the 1980s and 1990s. The concept of substantial equivalence emerged from the recognition that plants and animals we have long used for food provide a familiar baseline for comparison and for the evaluation of novel traits as we consider their safety. A number of factors are important, including:

The U.S. National Academy of Sciences explicitly endorsed this approach in its first paper on this topic, and reaffirmed it in 11 subsequent reports, which corroborated the safety of products produced with these methods. The safety of these products was reaffirmed in a comprehensive review of more than 1,700 peer-reviewed papers from the scientific literature over a decade, published in 2013, adding to a database of more than 2,000 such papers compiled by independent academics. It is noteworthy that based on their findings, independent academics and industry scientists reach identical conclusions. For these reasons, more than 275 scientific organizations have embraced the global scientific consensus on the safety of GM crops and foods. The European Union has summarized the safety issue thus:

Indeed, the use of more precise technology and the greater regulatory scrutiny probably make them even safer than conventional plants and foods; and if there are unforeseen environmental effectsnone have appeared as yetthese should be rapidly detected by our monitoring requirements. On the other hand, the benefits of these plants and products for human health and the environment become increasingly clear.

Process-Based Regulation Doesnt Work In the early 1980s, when the potential of recombinant DNA techniques to deliver solutions to problems in agriculture was first widely noted, two main schools of thought emerged on the best way to ensure their safety without discouraging innovation. Expert bodies around the world repeatedly found no unique or novel hazards associated with crops, livestock, microbes, or foods improved through biotechnology. They found that the foreseeable risks were similar to those with which we were long familiar with from classical plant and animal breeding throughout 10 millennia of domestication and agriculture. As a result, the United States, Canada, and Australia aimed to base regulations on experience and scientific data. U.S. policymakers, for example, concluded that existing regulations for risk assessment and management were sufficient, and determined to move forward with products of agricultural biotechnology under close scrutiny, with a watchful eye for surprises. This was attended by the expectation that regulations would be adapted regularly as knowledge and understanding accrued.

European politicians chose a different approach, and crafted new, process-specific regulations unrelated to any concrete demonstration of real hazards or actual risks, based instead on hypothetical potential harms. Following this lead, a number of other countries have also taken this precautionary approach and subordinated the findings of scientific risk assessment and experience to political and ideological interests. The results have been clear and dramatic; innovative products have rapidly swept to market dominance in countries that have chosen science-based approaches, while European farmers have become increasingly uncompetitive as innovators have fled the continent. The harshest condemnations of the failed European precautionary approach have come from Europeans.

But despite this reasoned approach early on, regulations in the United States more recently have not evolved to match our accumulated experience and the dramatic growth in our understanding. Regulations first laid down in 1987 have been significantly adapted to experience only once, in 1992. Since then, the disparity between the level of risk and the degree of regulation has expanded dramatically. This led the White House Office of Science and Technology Policy in 2015 to call for an updating of regulatory agencies responsibilities under the Coordinated Framework, the 1986 roadmap set forth to guide regulators into the new landscape. The new Trump administrations directive that each new regulation must be accompanied by repeal of two already in place is, in this arena at least, a step in the right direction.

The Purpose of Regulation Is to Manage Risk Regulations exist for a purpose: to manage and mitigate risks. Reasonable and effective regulations will also incorporate a consideration of economic costs and dynamic innovation effects. Thus, under the 1986 Coordinated Framework, the Animal and Plant Health Inspection Service is charged with managing risks that crops improved through biotechnology may present to American agriculture; the Environmental Protection Agency with ensuring that pesticides are used safely to manage pests and protect human and environmental health; and the Food and Drug Administration with ensuring that food and feed derived from crops or animals improved through biotechnology are as safe to consume as other food and feed.

But much of the oversight applied to crops improved through biotechnology in the United States has lost sight of the fundamental principle for determining risk, expressed in the equation: risk equals hazard times exposure. If there is no prospect for exposure to a hazard, then the hazard, no matter how great, presents no risk. If there is no hazard, or if it is present only at very low levels, then even high levels of exposure may be entirely irrelevant to human or environmental health. But in the regulatory systems now in place there is no relationship among the presence of a hazard, the level of exposure, and the degree of regulatory scrutiny applied. If innovation is to be enabled, much less encouraged, that must be remedied. But the importance of one other objective driving the adoption of regulations to deal with biotechnological innovations in agriculture cannot be overstated:

But the importance of one other objective driving the adoption of regulations to deal with biotechnological innovations in agriculture cannot be overstated:

In response to public concern [t]he goal in developing the Coordinated Framework was to explain to the American public that, for questions involving the products of biotechnology (more specifically, organisms derived from recombinant-DNA technology), human health and the health of the environment were of paramount concern and were adequately protected.

There is no denying the virtuous intent of that sentiment, for if consumers are not convinced that biotech foods are safe they will not buy them. But in fact, the promulgation of regulations in advance of any confirmed finding of hazard or demonstration of risk has not assuaged public concerns. Nor has the subsequent confirmation of safety led to areduction in regulatory oversight or regulatory delays in the deployment of innovative technologies and products. In fact, entrenched opposition from the very beginning has taken every emplacement of regulation as confirmation of the need for yet more stringent regulation, driven by the unfounded assertion of unique and technology-specific hazards.

This discordance between the degree of regulatory oversight and the actual hazards and risks confirmed by experience has only grown over the years, exacerbated by the emergence of regulation for the purpose of litigation-avoidance by the agencies. Special interest groups have brought a significant number of procedural lawsuits against USDA for approving specific crops improved through biotechnology, leading to lengthy delays in the dissemination of new products.23 The ephemeral success of these lawsuits hinged on deficiencies noted by the courts in the documentation of USDAs decision-making process. In no case have they identified any genuine hazard, and, after USDA repaired the paper record for its decision making, the products are now on the market. But the opportunity costs, both economic and environmental, imposed by the delays remain on the ledgers.

[Read the rest of the report here.]

This article originally appeared on The Information Technology and Innovation Foundations website under the title How the Trump Administration Can Unshackle Innovation in Agricultural Biotechnology and has been republished with permission from the author.

Val Giddings is Senior Fellow at the Information Technology & Innovation Foundation. He previously served as vice president for Food & Agriculture of the Biotechnology Industry Organization (BIO) and at the Congressional Office of Technology Assessment and as an expert consultant to the United Nations Environment Programme, the World Bank, USDA, USAID, and companies, organizations and governments around the world. Follow him on twitter @prometheusgreen.

For more background on the Genetic Literacy Project, read GLP on Wikipedia

View original post here:
Agricultural biotechnology regulations are a mess Here's how Trump can unshackle innovation - Genetic Literacy Project

President Macky Sall of Senegal has thrown his weight behind the adoption of agricultural biotechnology in the country.

.

President Sall made it clear that he supported the implementation of biotechnology in Senegal provided necessary measures to minimise risks were taken.

Macky Sall

I must say very clearly that I am for the use of GMOs based on the precautions taken and based on a dynamic regulation, otherwise we would be against progress. We must decide and step forward. We need to move forward because we have food security imperatives.

It is undeniable that GMOs can help meet current challenges, such as food insecurity, public health issues, natural resource conservation and climate change, he stressed.

We need serious thought to develop a strategy to maximise the use of GMOs, while mitigating the risks associated with them. That is why it is necessary to strengthen the National Biosafety Authority and to have an appropriate legal system combined with an efficient information system based on objective scientific values to assess the cost/benefit/risks ratio, he further stressed.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:GMOs: Senegal supports adoption of agric biotech

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Continued here:
President of Senegal bucks anti-biotechnology pressure: 'I am for ... - Genetic Literacy Project

The House of Representatives passed a bill for allotment of funds in an emergency pool earlier this week, which is to be used to counter the damaging effects of the coronavirus outbreak is expected to have on the domestic economy.

Let us analyze which stocks are expected to benefit from this emergency stash.

House Allocates $8 Billion to Emergency Funds

On Mar 4, the House passeda legislation that allocates more than $8 billion to emergency funds to battle against the spread of coronavirus. The bill won by a voting ratio of 415-2. Republican lawmakers Ken Buck of Colorado and Andy Biggs of Arizona were the only members who voted unfavorably.

The emergency funds aim to provide more than $3 billion for vaccine research and $2.2 billion for efforts in prevention and preparedness. Medical tests and vaccine research to combat the pandemic are urgent tasks right now, which many biotechnology firms in the country are working on actively.

Companies, such as Moderna, Inc. MRNA, Inovio Pharmaceuticals, Inc. INO and Vir Biotechnology, Inc. VIR are currently in the process of developing the much-needed vaccines.

The congressional spending proposal is considerably higher than the $2.5 billion that the White House had proposed in late February. The bill also authorizes about $500 million to allow Medicare providers to offer telehealth services, which would benefit elderly patients to receive care in the comforts of their homes.

The bill is now headed to the Senate for approval. Should it be passed effectively, it will then make its way to President Donald Trumps desk, who is expected to give a green signal. Trump had earlier indicated at a news conference that he would spend whatever is appropriate to fight the COVID-19 outbreak.

After all, death toll in the United States climbed to 11 and minimum 138 are infected. Of the 11, 10 deaths were confirmed from Washington while one was registered in California. Globally, the pandemic claimed more than 3,100 lives.

3 Stocks in Focus

We have, therefore, handpicked three vital stocks that are actively developing vaccines to address the novel coronavirus. One may take a closer look at these.

Modernais a clinical stage biotechnology company. Last week, the company saidthat its first batch of vaccine against the COVID-19 disease, called mRNA-1273, was ready for the government to test on humans.

The Zacks Consensus Estimate for Modernas current-year earnings has moved 5% north in the past 60 days. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 40.5% against the industrys decline of 2.6% on a year-to-date basis. (Read more)

Moderna carries a Zacks Rank #2 (Buy). You can seethe complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Inovio Pharmaceuticalson Mar 4 announcedan accelerated timeline to develop its DNA vaccine INO-4800 to battle COVID-19. Inovio's President & CEO Dr. J. Joseph Kim mentioned this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on Mar 2.

Inovio Pharmaceuticals carries a Zacks Rank #3. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 143.2% against the industrys decline of 2.6% on a year-to-date basis.

Story continues

Vir Biotechnologyis a clinical-stage immunology company. The firm, along with Alnylam Pharmaceuticals, Inc. ALNY, announcedon Mar 4 that the two companies would expand their continuing collaboration to make an attempt to develop RNA interference treatments for SARS-CoV-2.

Vir Biotechnology carries a Zacks Rank #3. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 257% against the industrys decline of 2.7% on a year-to-date basis.

Free: Zacks Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the companys drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportModerna, Inc. (MRNA) : Free Stock Analysis ReportAlnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis ReportInovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis ReportVir Biotechnology, Inc. (VIR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.

Read more:
House Okays $8 Billion Funds to Combat COVID-19: 3 Winners - Yahoo Finance

Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT Post Analyst Puma Biotechnology, Inc. (NASDAQ:PBYI) reached 85.92% versus a 1-year low price of $19.74. The stock was last seen 2.95% higher, reaching at $36.7 on Apr. 10, 2017. At recent session, the prices were hovering between $35.24 and $37.8. This company ... Brokerages Anticipate Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $0.00The Cerbat Gem Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$1.86 Per ShareBBNS Puma Biotechnology, Inc. (NYSE:PBYI): Trader Update on the ...Midway Monitor Sports Perspectives -NYSE Journal (press release) all 15 news articles »

More here:
Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT - Post Analyst

Even when a business is losing money, its possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, youd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So should Unity Biotechnology (NASDAQ:UBX) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Well start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Unity Biotechnology

A companys cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. Unity Biotechnology has such a small amount of debt that well set it aside, and focus on the US$113m in cash it held at September 2019. Importantly, its cash burn was US$71m over the trailing twelve months. That means it had a cash runway of around 19 months as of September 2019. While that cash runway isnt too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. The image below shows how its cash balance has been changing over the last few years.

Some investors might find it troubling that Unity Biotechnology is actually increasing its cash burn, which is up 25% in the last year. In light of that, the flat year on year operating leverage is a bit off-putting. In light of the data above, were fairly sanguine about the business growth trajectory. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Unity Biotechnology seems to be in a fairly good position, in terms of cash burn, but we still think its worthwhile considering how easily it could raise more money if it wanted to. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash to fund growth. We can compare a companys cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one years operations.

Unity Biotechnologys cash burn of US$71m is about 21% of its US$334m market capitalisation. Thats not insignificant, and if the company had to sell enough shares to fund another years growth at the current share price, youd likely witness fairly costly dilution.

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Unity Biotechnologys cash runway was relatively promising. Even though we dont think it has a problem with its cash burn, the analysis weve done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. For us, its always important to consider risks around cash burn rates. But investors should look at a whole range of factors when researching a new stock. For example, it could be interesting to see how much the Unity Biotechnology CEO receives in total remuneration.

Of course Unity Biotechnology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Continue reading here:
We Think Unity Biotechnology (NASDAQ:UBX) Needs To Drive Business Growth Carefully - Simply Wall St

Global Life Science Reagents Market was valued US$ 30 Bn in 2017 and expected to reach US$ 60 Bn by 2026, at a CAGR of 9.5% during forecast period.

Global life science reagents market is segmented into product, end-user, and region. On the basis of product, the market is divided into polymerase chain reaction (PCR) reagent kits, cell and tissue culture reagents, flow cytometry reagents, electrophoresis reagents, chromatography reagents, in-vitro diagnostics (IVD) reagents, others (gene expression reagents, mass spectroscopy reagents, and transfection reagents). Based on end-user, the market is classified into commercial and contract manufacturers, research and academic institutions, clinical laboratories, forensic laboratories. Geographically market is spread into North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa.

Request for Report sample : https://www.trendsmarketresearch.com/report/sample/10443

The life science and analytical reagents market is driven by the increasing use of reagents in basic research, therapeutics, and commercial applications. Request for biotechnology reagents is mostly dependent on the development of the biotechnology instrumentation market. The biotechnology instrumentation market continues to witness important growth because of an increase in the number of biotechnology firms and rises in research and development spending by biotechnology companies, thus boosting the demand for biotechnology instruments.

North America accounted for the largest share of the global life science reagents market, accounting for 35% share in 2017. Europe is holding the second largest share of the global market in 2017. Well-established health care infrastructure, the large base of pharmaceutical and biotechnology industries, rapidly growing geriatric population has led to dominant shares of North America and Europe.

Request for Report Discount: https://www.trendsmarketresearch.com/report/discount/10443

Key players operated in life science reagents market are life technologies, bio-rad, thermo fisher scientific, water corporation, Sigma-Aldrich, Agilent technologies inc., betcon Dickinson, Beckman colter, Abbott (u.s.), ortho clinical diagnostics, biomrieux sa, Sysmex Corporation, and diasorin s.p.a., f. Hoffmann-la Roche ag, Danaher Corporation, Siemens healthiness (siemens ag), Merck kgaa, ge healthcare, bio-techne corp, Bruker Corp, Perkin Elmer inc., Qiagen n.v., (includes bd life sciences), Illumina inc., Roche, Promega corp., Beckman coulter, inc., biomerieux, inc., Lonza group ltd., Merck Millipore, meridian life science, Inc.Scope of Global Life Science Reagents Market:Life Science Reagents Market by Product:Chromatography ReagentsMolecular Diagnostic ReagentsImmunoassay ReagentsClinical Chemistry ReagentsFlow Cytometry ReagentsCell & Tissue Culture ReagentsHematology & Hemostasis ReagentsMicrobiology ReagentsOthers (Histology & Cytology Reagents, Electrophoresis Reagents, Investigational Markers)Life Science Reagents Market by End-User:Hospitals and Diagnostics LaboratoriesCommercial & Contract Research ManufacturersAcademic & Research InstitutesOthersLife Science Reagents Market by Region:North AmericaLatin AmericaAsia-PacificEurope

Make an Inquiry before Buying@: https://www.trendsmarketresearch.com/checkout/10443/Single

Middle East & AfricaKey Players Operated In Global Life Science Reagents Market:life technologiesbio-radthermo fisher scientificwater corporationsigma-Aldrichagilent technologies inc.betcon Dickinsonbeckman coulterabbottortho clinical diagnosticsbiomrieux sasysmex corporationdiasorin s.p.a.F. Hoffmann-la Roche agdanaher corporationsiemens healthineers (siemens ag)merck kgaaGE Healthcarebio-techne corpbruker corpperkin Elmer Inc.qiagen n.v., (includes bd life sciences)illumina inc.rochepromega corp.beckman coulter, Inc.biomerieux, Inc.lonza group ltd.merck Milliporemeridian life science, inc

Follow this link:
Life Science Reagents Market 2018, Trend, CAGR Status, Growth, Analysis and Forecast to 2026 - Kentucky Journal 24

We welcome guest writers to all of our Todayville platforms. Heres a submission from Emily Folk. Emily is passionate about agricultural sustainability and more of her work can be found on her site,Conservation Folks. In this story, Emily Folk explains the USMCA Impact on Agriculture.

The United States Mexico Canada Agreement (USMCA) has been in the news a lot lately. The leaders of the respective nations signed the trade agreement on November 30, 2019, and ratification is pending. You can think of the USMCA as an updated version of the North American Free Trade Agreement (NAFTA).

U.S. President Donald Trump vowed to renegotiate NAFTA after publicly speaking unfavourably about it. The USMCA is the result of that vow. The agreement spans several areas, such as the origin of automobile parts and new labor laws in Mexico that make it easier for workers to unionize. The USMCA also has a sunset clause that makes its terms expire after 16 years. Plus, every six years, the leaders of the countries involved must agree on whether to extend the deal.

Some agriculture-specific stipulations also exist within the USMCA. Additionally, the agreement notably mentions biotechnology. Heres a closer look at how the USMCA might change these two industries.

One of the key points often mentioned about the USMCA is that parties expect the agreement to cause a $2 billion increase in U.S. agriculture exports, triggering a $65 billion rise in U.S. gross domestic product (GDP). Canada and Mexico are currently the top two exporting markets for American farmers, supporting more than 325,000 American jobs. In 2018, the food and agricultural exports destined for Canada and Mexico totaled more than $39.7 billion.

The USMCA also opens exporting opportunities that did not exist before. Now, U.S. dairy farmers will have expanded access to send products such as fluid and powdered milk, cheese and cream to Canadian parties. There will also no longer be U.S. tariffs on whey and margarine. This change is notable, considering the Canadian dairy market produced roughly 17% of the United States annual output over the past three years.

In exchange, Canada will give the United States new access to chicken and eggs, plus increased access to turkey. Plus, all other agriculture products traded between the U.S. and Mexico will be under a zero-tariff model.

Another improvement associated with the USMCA is that it looks at agricultural technology more broadly than other trade agreements have.

For example, the Trans-Pacific Partnership a proposed trade agreement between 12 nations only addressed biotechnology regarding recombinant DNA (rDNA). That process involves joining the molecules from two different species, then inserting the product into a host to create new genetic combinations. Instead, the USMCA opens possibilities for all kinds of agricultural technology, including gene editing. Moving ahead with biotechnology could be crucial for addressing pressing matters that affect agriculture, such as water scarcity.

Approximately 700 million people suffer from water scarcity, and that number could double by 2025. Also, the agriculture industry is the greatest user of water. Things must change both to address the growing water scarcity problem and to give farmers more options for growing things without using so much water.

Biotechnology has already helped, and it seems highly likely to continue spurring progress. In one example, scientists altered the expression of one gene common to all plants. This change led to a 25% increase in the plants water-use efficiency without adversely impacting yield or photosynthesis.

As part of the USMCA, Mexico, Canada and the United States agreed to improve information sharing and cooperation about biotechnology matters related to trade. That change could speed new developments, resulting in positive outcomes for all involved groups and the world at large.

A grading system for agricultural products defines trading procedures. For example, commercial buyers of a product grown in another country refer to the grading standards to set expectations about a products quality. The USMCA specifies that Canada will evaluate U.S. imported wheat and assign it a grade no less favourable than it would give Canadian-grown wheat.

Canada will also no longer require country of origin statements associated with inspection certificates or quality grades. The United States and Canada will discuss issues related to seed regulations under the USMCA, too.

Concerning Mexico and the United States, the two countries agreed to non-discriminatory grading standards and services. Moreover, a dialogue will begin between the two countries to flesh out the details for quality standards and grading regarding trade.

Its too early to say what the real-life effects will be of the changes outlined here. But, the commitments laid out within the USMCA seem like theyll represent clear improvements for agriculture professionals, as well as everyone who benefits from their goods.

Im Emily Folk, and I grew up in a small town in Pennsylvania. Growing up I had a love of animals, and after countless marathons of watching Animal Planet documentaries, I developed a passion for ecology and conservation. You can read more of my work by clicking this link: Conservation Folks.

Extreme Weather Patterns Causing State of Agricultural Emergency in Canada

Read more:
What the USMCA Might Mean for Agriculture and Biotechnology? - Todayville.com

According to Dr. Rana Khan, the MS in Biotechnology Management and Entrepreneurship (BME) at the Katz School of Science and Health is one of a handful of national biotechnology graduate programs that are interdisciplinary in nature and focused on entrepreneurship. Dr. Khan, the founding director of the program, noted that what makes the program stand out is that our students learn by doing and are exposed to various aspects of biotechnology industry via case studies, guest speakers and hands-on projects.

On Monday, Dec. 16, 2019, five students presented their capstone projects, becoming the first cohort of students to complete the requirements for the masters degree. Robert Friedman 78YC, the professor in the biotechnology management course for which the students were doing their presentations, noted that purpose of the capstone is for the students to integrate as much as possible from what they have learned at BME.

Each capstone project is structured around a selected company. The student, using information culled from a multitude of sources, creates, in essence, a business plan for the company that examines such areas as the companys product, potential competitors and allies, possible markets and advertising plans for accessing those markets, to name just a few of the areas covered by the project. The goal is to create a plan that will help the company increase its market presence, improve its performance and make it more attractive to potential investors.

The five students were given their final assignments based on projects solicited from companies and assigned them based on the fit as determined by the course professor and the programs director. Creation of the presentation started essentially on the first day of class, said Friedman. The class met at regular intervals and provided updates on their research projects in PowerPoint presentation format. In essence, they were creating the final document at every step of the research process.

To make the project even closer to real life, students and faculty signed non-disclosure agreements prior to commencing work. As in most strategic consulting processes, Friedman explained, the company maintains intellectual property rights to the work produced, except to the elements of the report that were not confidential and were sourced from publicly available information.

Here are the five presentations:

Alana ReichenbergLibra@Home uses portable virtual reality technologies to present physical therapy exercises to motivate patients to take an active role in their therapy. The company is based in Jerusalem. Alana researched the physical therapy equipment market to identify the key players, understand their business model and define the value proposition that Libra@Home system requires to be a fit for these distributors to commercialize the product.

Josh LankinSFA Therapeutics is a development-stage bio-pharmaceutical startup company. Josh developed a business plan focusing on SFA Therapeutics core business of developing microbiome-derived drugs to treat chronic inflammatory diseases.

Devorah LammFor MatterBio, Devorah studied the current and future competitive landscape of gene therapy in cancer, outlined and compiled the intellectual property connected to certain key technologies and translated her research into an investor-ready vision for fund-raising.

Surosri Banerje and David WallachBoth students developed plans for ChalkSense, a data-driven and customer-centric management consulting service whose motto is making sense from the data dust. Surosi developed an analysis and preliminary strategy for an exploratory stage endeavor in the drug-device combination space for insulin pump improvements. David put together an integrated business strategy for EndpointGenie, an artificial intelligence assistant tool that enables strategic endpoint design and execution.

YU News had the pleasure of sitting in on the presentation done by Alana Reichenberg for Libra@Home, who had the honor of being the first out of the gate.

Connected to her contacts in Israel, Dario Geiseninger (founder and CEO) and Lacey McBride (business development and clinical liaison), through a Zoom conference room, Reicheberg presented step-by-step her findings about how Libra@Home might access markets in the United States and the challenges to the company in doing so, including a review of potential competitors in the world of providing physical therapy services.

At the end of the presentation, Reichenberg was critiqued by Friedman, Dr. Khan and Dr. Maria Blekher, director of the Innovation Lab, who sat in on the meeting. They all agreed that the plan presented was solid, and they also offered other avenues to pursue for research, such as Dr. Blekhers suggestion of reaching out to early adapters of technology, who might be more open to Libra@Homes software approach than companies more invested in other kinds of equipment and approaches.

Relieved to have done well, Reichenberg was also buoyed by the way the capstone project had sharpened and expanded her skills, especially because she wants to find employment as a clinical trial coordinator. As an undergraduate at Stern College, I had a major in biology and a minor in business management, she noted. I wanted to find a path that incorporated both, which is exactly what the BME program has given me. I have learned so much from my professors, the guest speakers and my fellow classmates. I am proud to be part of the first cohort to complete this program because I know this is just the beginning.

This is precisely what Dr. Khan and Friedman hoped the capstones would do for the students. Working on a project like this, said Dr. Khan, gives students firsthand experience of the issues biotechnology businesses have to research/consider at different stages. It expands our students professional network and provides opportunities for employment/recommendation letters. Furthermore, said Friedman, students learn how to put together a presentation for investors and to communicate effectively, both orally and in writing, within a given time. This is also something that will go on their resumes. He added that on a personal level, it has been a most gratifying experience; in some ways, I have learned as much, if not more, from my students than they have learned from me!

Find more information on the program at go.yu.edu/katz/biotechnology-management

Read more:
Investigating the World of Biotechnology Management and Entrepreneurship - Yu News

NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been selected for addition to the NASDAQ Biotechnology Index (^NBI), as part of the annual index evaluation. The Companys addition to the index will become effective prior to the market open on Monday, December 23, 2019.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NASDAQ Biotechnology Index must also meet certain other eligibility criteria, including minimum market capitalization, average daily trading volume, and seasoning as a public company. The index forms the basis for a number of Exchange Traded Funds (ETFs).

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsomes core CNS product candidate portfolio includes four clinical-stage candidates, AXS-05, AXS-07, AXS-09, and AXS-12. AXS-05 is currently in a Phase 3 trial in treatment resistant depression (TRD), a Phase 2/3 trial in agitation associated with Alzheimers disease (AD), and is being developed for major depressive disorder (MDD). AXS-05 is also being developed for smoking cessation treatment. AXS-07 is currently in two Phase 3 trials for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-05, AXS-07, AXS-09, and AXS-12 are investigational drug products not approved by the FDA. For more information, please visit the Companys website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.

Forward Looking Statements

Certain matters discussed in this press release are forward-looking statements. We may, in some cases, use terms such as predicts, believes, potential, continue, estimates, anticipates, expects, plans, intends, may, could, might, will, should or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Companys statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (NDA) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (FDA) or other regulatory authority approval of, or other action with respect to, our product candidates (including, but not limited to, FDAs agreement with the Companys plan to discontinue the bupropion treatment arm of the ADVANCE-1 study in accordance with the independent data monitoring committees recommendations); the potential for the ASCEND clinical trial, combined with the GEMINI clinical trial results, to provide a basis for approval of AXS-05 for the treatment of major depressive disorder and accelerate its development timeline and commercial path to patients; the Companys ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Companys research and development programs and collaborations; the success of the Companys license agreements; the acceptance by the market of the Companys product candidates, if approved; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings prior to the readout from its Phase 3 trials; and other factors, including general economic conditions and regulatory developments, not within the Companys control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

Story continues

Axsome Contact: Mark JacobsonSenior Vice President, OperationsAxsome Therapeutics, Inc.200 Broadway, 3rd FloorNew York, NY 10038Tel: 212-332-3243Email:mjacobson@axsome.comwww.axsome.com

Original post:
Axsome Therapeutics Added to NASDAQ Biotechnology Index - Yahoo Finance

Biotechnology is the use of living organisms, or products of living organisms, for human benefit, and it has had a tremendous impact on many aspects of modern life. Its effects, however, are perhaps most keenly felt within the food/agricultural and medical fields. Biotechnological processes are used in the production of specific foods and have allowed the genetic modification of food crops to be hardier and to have increased nutritional value. The health care sector likewise has benefited from biotechnology to produce medicines and vaccines that prevent or cure disease. Moreover, biotechnological theory and methodologies will be central to the realization of personalized medicine.

At Drexel University, we are proud to offer the Master of Science in Biotechnology (BIOT), an innovative, non-thesis graduate degree program that emphasizes hands-on training in state-of-the-art laboratory techniques used across the biotechnology and biomedical industries.

This program furnishes students with the necessary technical skills to successfully seek gainful employment in both biotechnology/pharmaceutical firms and academic laboratories. It does so by using a two-pronged approach that combines theory with hands-on instruction under the direct supervision of our diverse and accomplished research faculty. The program is appropriate for recent college graduates or experienced technicians wishing to bolster their methodological base.

The Master of Science in Biotechnology program is ideally suited for enhancing the scientific skill set of the following groups:

"The Biotechnology master's program provided me with an excellent opportunity to gain a diverse set of technical skills, including those in biochemistry, biophysics and molecular biology, while exploring multiple areas of biomedical research. In addition, the experienced principal investigators and accelerated course work strengthened the knowledge I had gained throughout undergrad. Overall, the programs productive and focused curriculum at both the bench and in the classroom left me well qualified for positions in both academia and industry. On the strength of the Biotechnology Master of Science program at Drexel University, I have successfully secured positions in local biotech/pharma, and now work in the Screening Group at Janssen R&D (Johnson & Johnson) as an associate scientist."Jeff Branson, Class of 2016

The program encompasses both classes and hands-on practica. It is the inclusion of practica that makes this program unique, stressing applied learning of key methodologies used throughout academia and industry and their practical use in addressing research questions in bioscience and biomedicine. This innovative combination of technical theory and application will provide graduates of this program with a knowledge base and a set of skills that will make them very competitive for laboratory jobs in the academic or industrial sectors or enhance their potential for advancement at their current place of employment.

Swetaben Patel and Aishwarya Subramanian have taken positions at GlaxoSmithKline.

Lina Maciunas is currently pursuing a PhD at Drexel and works in the Loll Laboratory.

Jeff Branson is currently working as an associate scientist at Janssen R&D (Johnson & Johnson) in the Screening Group.

Ayonika Mukherjee has an internship at GlaxoSmithKline.

More:
Master of Science in Biotechnology - Drexel University ...